Mayo Clinic Ventures

Mayo Clinic Ventures invests in companies whose technologies directly align with Mayo's clinical and research mission, with the expectation that Mayo's clinicians can serve as development partners or early adopters. The thesis is anchored in deploying the institution's balance sheet, not third-party LP capital. Every investment requires a clinical champion within Mayo who validates the technology's potential impact on patient care.

The unit operates under Mayo Clinic's corporate umbrella and reports through the institution's corporate development function rather than through an external GP structure. Investment committees draw on practicing Mayo physicians and researchers alongside venture professionals, giving clinical-use-case evaluation a direct seat at the table. Ultimate governance rests with Mayo's Board of Trustees, which evaluates both financial returns and mission alignment.

No. Mayo Clinic Ventures deploys capital directly from Mayo Clinic's own balance sheet and does not raise third-party LP commitments. This makes it a corporate venture capital entity rather than a traditional fund—the unit faces no fundraising cycles and is not bound by the typical 10-year fund-life constraints that shape conventional VC behavior.

The portfolio concentrates on medical devices, diagnostics, digital health, healthcare IT, and AI-driven clinical software. The unit avoids areas disconnected from its clinical enterprise—consumer wellness without a clinical pathway, pure pharmaceutical plays without a companion diagnostic component, or therapeutic assets where Mayo lacks internal clinical research depth. Investments outside US healthcare are rare unless a clear FDA regulatory pathway exists.

Yes. The unit frequently co-invests in syndicates with life-science VCs including OrbiMed and New Enterprise Associates. Mayo's stance is that its clinical validation signal can complement pure financial VC diligence. The unit also acts as a lead investor on rounds where Mayo's clinical partnership offers the startup a deployment edge that financial VCs alone cannot provide.

Exits are evaluated against a dual metric: financial return—which flows back to Mayo's clinical and research operations—and mission impact, meaning whether the technology reached patients through Mayo's own system or the broader market. The unit's permanent-capital posture allows it to hold positions through lengthy FDA regulatory processes without forced secondary sales or fire-sale liquidity events.

Deal flow originates primarily from Mayo's own clinical and research staff—a network of roughly 7,000 physicians and scientists who encounter emerging technologies in the course of their work. External founders typically gain access by presenting to a Mayo clinician willing to champion the technology internally. The unit does not accept unsolicited pitch decks without a clinical-advocate introduction, a filtering mechanism that distinguishes it from volume-driven venture platforms.